ELISA for determination of total coagulation factor XII concentration in human plasma

2013 ◽  
Vol 394 (1-2) ◽  
pp. 32-39 ◽  
Author(s):  
Daniel Elenius Madsen ◽  
Johannes Jakobsen Sidelmann ◽  
Kathrine Overgaard ◽  
Claus Koch ◽  
Jørgen Brodersen Gram
1985 ◽  
Vol 839 (1) ◽  
pp. 57-61 ◽  
Author(s):  
Kumudini M. Weerasinghe ◽  
Michael F. Scully ◽  
Vijay V. Kakkar

Author(s):  
D H Osmond ◽  
S R Tatemichi ◽  
E A Wilczynski ◽  
A D Purdon

We have demonstrated that human plasma “prorenin”, an inactive precursor of the blood pressure regulating enzyme renin, can be activated by cold, e.g. -4 to +4°C for 1-30 days (Can. J. Physiol. Pharmacol. 51:705, 1973). Several workers have reported cold activation of the coagulation system. Suspecting a link between these two cold- activated enzyme systems, we established that in factor XII deficient plasma, the rate of cold activation of prorenin is halved (Lancet i, 1313, 1978). Trypsinization of plasma can mimic within 1 minute the effect of prolonged cold (Circ. Res. Suppl . 1, 41:171, 1977), and can overcome specific coagulation factor deficiencies in varying degrees. FXII, VII, V, and especially FX deficient plasmas, all have subnormal basal active renin levels, implying an impaired state of prorenin conversion in vivo. FXII deficientplasma activates least by cold, suggesting special importance of FXII for operation of cold activation. All the plasmas activate better with 0.5 mg trypsin/ml plasma than with cold, except FX, suggesting that it especially mediates tryptic activation. Increasing the trypsin concentration corrects for factor deficiencies in varying degrees, implying some non-specificity and interchangeability of factor requirements for prorenin activation. Our data point to a hierarchy of factor importance, and to a “cascade7#x201D; of prorenin activation, by which plasma renin content can be rapidly increased. Thus, plasma renin activity is a function of renal release of renin, plus renin formation from renal (and possibly extrarenal) prorenin by an activation process involving the coagulation system.


2011 ◽  
Vol 83 (6) ◽  
pp. 2317-2323 ◽  
Author(s):  
Mi-Hye Kwon ◽  
Deok-Hoon Kong ◽  
Se-Hui Jung ◽  
In-Bum Suh ◽  
Young-Myeong Kim ◽  
...  

Author(s):  
Abdulmajeed Alharbi ◽  
Neha Iyer ◽  
Ayah AlQaryoute ◽  
Revathi Raman ◽  
David Burks ◽  
...  

Hemolytic disorders are characterized by hemolysis and are prone to thrombosis. Previously, it has been shown that the RNA released from damaged blood cells activates clotting. However, the nature of RNA released from hemolysis is still elusive. We found that after hemolysis, RBCs from both zebrafish and humans released 5.8S rRNA. This RNA activated coagulation in zebrafish and human plasmas. Using both natural and synthetic 5.8S rRNA and its truncated fragments, we found that the 3'-end 26 nucleotide-long RNA (3'-26 RNA) and its stem-loop secondary structure were necessary and sufficient for clotting activity. Corn trypsin inhibitor (CTI), a coagulation factor XII (FXII) inhibitor blocked 3'-26 RNA-mediated coagulation activation of both zebrafish and human plasma. CTI also inhibited zebrafish coagulation in vivo. 5.8S rRNA monoclonal antibody inhibited both 5.8S rRNA- and 3'-26 RNA-mediated zebrafish coagulation activity. Both 5.8S rRNA and 3'-26 RNA activates normal human plasma but did not activate FXII-deficient human plasma. Taken together, these results suggested that the activation of zebrafish plasma is via FXII-like protein. Since zebrafish has no FXII and hepatocyte growth factor activator (Hgfac) has sequence similarities to FXII, we knocked down the hgfac in adult zebrafish. We found that plasma from this knockdown fish does not respond to 3'-26 RNA. In conclusion, we identified 5.8S rRNA released in hemolysis activates clotting in human and zebrafish plasma. Only 3'-end 26 nucleotides of the 5.8S rRNA is needed for the clotting activity. Furthermore, we showed that fish Hgfac plays a role in 5.8S rRNA-mediated activation of coagulation.


2001 ◽  
Vol 69 (6) ◽  
pp. 3877-3882 ◽  
Author(s):  
Eva Mattsson ◽  
Heiko Herwald ◽  
Henning Cramer ◽  
Kristin Persson ◽  
Ulf Sjöbring ◽  
...  

ABSTRACT Staphylococcus aureus is a prominent human pathogen. Here we report that intact S. aureus bacteria activate the contact system in human plasma in vitro, resulting in a massive release of the potent proinflammatory and vasoactive peptide bradykinin. In contrast, no such effect was recorded withStreptococcus pneumoniae. In the activation of the contact system, blood coagulation factor XII and plasma kallikrein play central roles, and a specific inhibitor of these serine proteinases inhibited the release of bradykinin by S. aureus in human plasma. Furthermore, fragments of the cofactor H-kininogen of the contact system efficiently blocked bradykinin release. The results suggest that activation of the contact system at the surface ofS. aureus and the subsequent release of bradykinin could contribute to the hypovolemic hypotension seen in patients with severeS. aureus sepsis. The data also suggest that the contact system could be used as a target in the treatment of S. aureus infections.


Sign in / Sign up

Export Citation Format

Share Document